Authors
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
How Voice Recognition Technologies Can Be Used to Accelerate Patient TrialsBecause of the growing rate of voice assistant applications, such as Alexa, healthcare and life sciences organizations are beginning to design a range of scenarios for deploying these voice assistant platforms in the clinical trial setting.
Latest:
The Hidden Costs of Paper-Based Clinical Outcome AssessmentsClinical trials using electronic Clinical Outcome Assessments (eCOA) benefit from compliance rates 300% higher than paper-based studies - but some sponsor shy away from eCOA adoption due to a misconception that paper diaries are cheaper. Read our eBook to understand the frequently neglected cost calculations proving that eCOA is the cost-effective and superior data collection solution for many clinical trials.
Latest:
Operational Challenges for Biosimilar StudiesUsing strategic planning to address hurdles in biosimilar development programs from the outset.
Latest:
Operational Challenges for Biosimilar StudiesUsing strategic planning to address hurdles in biosimilar development programs from the outset.
Latest:
Recruiting Diabetes SubjectsThe disconnect coordinating and connecting interested patients to clinical trials is an ongoing struggle.
Latest:
The 3 Essential Factors Affecting FDA Inspection OutcomeThis article focuses on the 3 essential factors that have a significant impact on the outcome of any inspection or audit. The author applies this primarily to GCP (Good Clinical Practice) inspections, but the principles are universal, being applicable to any government inspection such as the FDA (U.S. Food & Drug Administration) or industry QA (Quality Assurance) audit.
Latest:
eCOA Increases Patient-Site Communication and CandorWorldwide Clinical Trials recently announced the results of a survey that evaluated the perceptions of clinical trial site investigators who use electronic clinical outcome assessment (eCOA) technologies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
Personalized Medicine DevelopmentAs the popularity of personalized medicine grows the role of the CRO continues to evolve.
Latest:
Set the Course for a More Engaging & Productive Patient & Clinical Trial Site JourneyDiscover how evolving clinical trial trends are reshaping patient and site experiences—and the steps sponsors can take to stay ahead—in this conversation with uMotif CEO Steve Rosenberg at SCOPE Summit 2025.
Latest:
Learning from Failure, Leveraging Biosimulation for Pediatric Drug Development SuccessPediatric trials now feature increased modeling and analytics for safer drug dosing and response.
Latest:
Learning from Failure, Leveraging Biosimulation for Pediatric Drug Development SuccessPediatric trials now feature increased modeling and analytics for safer drug dosing and response.
Latest:
Developing New Clinical Endpoints for Immuno-Oncology StudiesDrug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.
Latest:
Improving Patient Engagement through eCOAHow the adoption of electronic clinical outcome assessment in trials can drive increased communication and patient reporting of events.
Latest:
FSP Outsourcing in Clinical Research: Trends and OpportunitiesWhen drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
Latest:
Clinical Trials in Kazakhstan: Open For BusinessThis brief overview of Kazakhstan presented by Vlad Bogin will help you get acquainted with this emerging clinical trial location.
Latest:
Interexpert Agreement on Adverse Events’ EvaluationStudy measures the differing judgment levels between clinical investigators and drug safety experts.
Latest:
Interexpert Agreement on Adverse Events’ EvaluationStudy measures the differing judgment levels between clinical investigators and drug safety experts.
Latest:
Interexpert Agreement on Adverse Events’ EvaluationStudy measures the differing judgment levels between clinical investigators and drug safety experts.
Latest:
Interexpert Agreement on Adverse Events’ EvaluationStudy measures the differing judgment levels between clinical investigators and drug safety experts.
Latest:
Leverage Site-Owned Tech to Improve Trial RetentionMajor Depressive Disorder patients display a reduced ability to feel pleasant experiences known as Anhedonia. Such a feature provides difficulties when treating depression and engaging patients during clinical trials.
